A Phase 1 interventional study of Cisticid and Biltricide in Healthy, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Mexico. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-18.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this trial is to assess the bioequivalence (BE) of new 600 milligram (mg) Cisticid tablet (Test) versus 600 mg Biltricide tablets (Reference) at a dose of 1200 mg in healthy male participants. Praziquantel (PZQ) is the active ingredient for Cisticid and Biltricide tablets.
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cisticid (Test) in Treatment Period 1 followed by Biltricide (Reference) in Treatment Period 2 and Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
Drug: Cisticid · Drug: Biltricide
Biltricide (Reference) in Treatment Period 1 followed by Cisticid (Test) in Treatment Period 2 and then Biltricide (Reference) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
Drug: Cisticid · Drug: Biltricide
Biltricide (Reference) in Treatment Period 1 and Treatment Period 2 followed by Cisticid (Test) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
Drug: Cisticid · Drug: Biltricide
Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).
Also known as: Praziquantel
Participants received 600 mg of Biltricide (Reference) tablet at a dose of 1200 mg on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Also known as: Praziquantel
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of L-Praziquantel (L-PZQ)
Area under the plasma concentration-time curve from 0 to the time of the last quantifiable concentration.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of L-Praziquantel (L-PZQ)
The maximum observed plasma concentration of L-Praziquantel (L-PZQ).
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Time to Reach Maximum Plasma Concentration (Tmax) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
Time of the maximum drug concentration.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
Time prior to the first measurable (non-zero) concentration; calculated as last time point at which the concentration is less than (\<) Lower Limit of Quantification (LLOQ) before the occurrence of the first quantifiable concentration.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
AUC0-inf is defined as the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Extrapolated Area Under the Plasma Concentration Curve From Time Tlast to Infinity (AUCextra) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
AUCextra was reported in terms of percentage of AUC0-inf.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Terminal Elimination Half-Life (t1/2) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
Elimination Half Life (t1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Terminal Elimination Rate Constant (Lambda Z) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
Lambda Z was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Apparent Clearance (CL/f) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Apparent Volume of Distribution During Terminal Phase (Vd/f) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vd/f after oral dose was influenced by the fraction absorbed.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Racemate PZQ (Rac-PZQ)
Area under the drug plasma concentration-time curve from time zero to the time last measurable concentration.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of Racemate PZQ (Rac-PZQ)
The maximum observed plasma concentration of rac-Praziquantel (rac-PZQ).
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
An adverse event (AE) was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs.
Time frame: Baseline up to Day 29
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
Number of participants with clinically significant abnormalities in laboratory parameters were reported. Laboratory investigation included hematology, biochemistry, urinalysis and coagulation.
Time frame: Baseline up to Day 29
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Number of participants with clinically significant abnormalities in vital signs were reported. Vital signs included body temperature, systolic / diastolic blood pressure, and pulse rate.
Time frame: Baseline up to Day 29
Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings
Number of participants with clinically significant abnormalities in 12-lead electrocardiogram (ECG) were reported. The 12-lead ECGs were recorded after the participants have rested for at least 5 minutes in supine position.
Time frame: Baseline up to Day 29
| Milestone | First Cisticid, Then Biltricide, Then Biltricide | First Biltricide, Then Cisticid, Then Biltricide | First Biltricide, Then Biltricide, Then Cisticid |
|---|---|---|---|
| Started | 20 | 20 | 20 |
| Completed | 20 | 20 | 19 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Milestone | First Cisticid, Then Biltricide, Then Biltricide | First Biltricide, Then Cisticid, Then Biltricide | First Biltricide, Then Biltricide, Then Cisticid |
|---|---|---|---|
| Started | 20 | 20 | 19 |
| Completed | 20 | 20 | 19 |
| Not completed | 0 | 0 | 0 |
| Milestone | First Cisticid, Then Biltricide, Then Biltricide | First Biltricide, Then Cisticid, Then Biltricide | First Biltricide, Then Biltricide, Then Cisticid |
|---|---|---|---|
| Started | 20 | 20 | 19 |
| Completed | 20 | 20 | 19 |
| Not completed | 0 | 0 | 0 |
Area under the plasma concentration-time curve from 0 to the time of the last quantifiable concentration.
| Hour*nanogram per milliliter (h*ng/ml) | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of L-Praziquantel (L-PZQ) | 441.53 ± 345.70 | 547.41 ± 384.82 | 460.25 ± 343.37 |
The maximum observed plasma concentration of L-Praziquantel (L-PZQ).
| ng/mL | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of L-Praziquantel (L-PZQ) | 310.87 ± 249.02 | 426.42 ± 324.01 | 363.20 ± 333.50 |
Time of the maximum drug concentration.
| hours | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| L-PZQ | 2.5 (1.5 to 5.5) | 2 (1 to 3.5) | 2.5 (1 to 4.5) |
| Rac-PZQ | 2.5 (1.5 to 5.5) | 2 (1 to 3.5) | 2.5 (1 to 4.5) |
Time prior to the first measurable (non-zero) concentration; calculated as last time point at which the concentration is less than (\<) Lower Limit of Quantification (LLOQ) before the occurrence of the first quantifiable concentration.
| hours | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| L-PZQ | 1 (0.25 to 3) | 1 (0.25 to 2.5) | 1 (0.25 to 3.5) |
| Rac-PZQ | 0.75 (0.00 to 2.00) | 0.75 (0.25 to 2.00) | 0.75 (0 to 2.5) |
AUC0-inf is defined as the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
| h*ng/ml | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| L-PZQ | 468.52 ± 352.29 | 584.23 ± 410.05 | 497.89 ± 348.81 |
| Rac-PZQ | 2130.19 ± 1417.81 | 2509.42 ± 1624.33 | 2189.25 ± 1403.14 |
AUCextra was reported in terms of percentage of AUC0-inf.
| Percentage of AUC0-inf | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| L-PZQ | 5.36 ± 3.73 | 5.49 ± 6.47 | 5.74 ± 4.02 |
| Rac-PZQ | 2.60 ± 1.73 | 2.84 ± 2.56 | 2.57 ± 1.56 |
Elimination Half Life (t1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.
| hours | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| L-PZQ | 1.87 ± 1.12 | 2.59 ± 3.01 | 2.32 ± 1.65 |
| Rac-PZQ | 2.19 ± 0.91 | 2.54 ± 1.73 | 2.18 ± 0.90 |
Lambda Z was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method.
| Per hour | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| L-PZQ | 0.452927 (0.103378 to 1.120808) | 0.383267 (0.032567 to 0.721124) | 0.370854 (0.073375 to 0.944209) |
| Rac-PZQ | 0.365639 (0.135661 to 0.646499) | 0.331359 (0.060282 to 0.635357) | 0.370806 (0.125134 to 0.638226) |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
| Milliliter per hour | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| L-PZQ | 749261.50 ± 744206.88 | 585260.42 ± 541013.95 | 673193.51 ± 531848.19 |
| Rac-PZQ | 147268.6 ± 122977.13 | 128110.14 ± 122864.03 | 155851.99 ± 145104.37 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vd/f after oral dose was influenced by the fraction absorbed.
| Milliliter | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| L-PZQ | 1540237.10 ± 1069504.21 | 1660474.33 ± 1619772.26 | 1800582.47 ± 1385707.17 |
| Rac-PZQ | 430368.23 ± 328721.73 | 385223.26 ± 279076.69 | 431494.33 ± 350782.53 |
Area under the drug plasma concentration-time curve from time zero to the time last measurable concentration.
| h*ng/ml | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Racemate PZQ (Rac-PZQ) | 2071.35 ± 1370.58 | 2421.73 ± 1518.94 | 2131.01 ± 1353.64 |
The maximum observed plasma concentration of rac-Praziquantel (rac-PZQ).
| ng/mL | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Racemate PZQ (Rac-PZQ) | 1209.15 ± 803.20 | 1530.23 ± 944.12 | 1356.18 ± 1011.46 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs.
| Participants | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| Participants with TEAEs | 2 | 5 | 6 |
| Participants with Serious TEAEs | 0 | 0 | 0 |
Number of participants with clinically significant abnormalities in laboratory parameters were reported. Laboratory investigation included hematology, biochemistry, urinalysis and coagulation.
| Participants | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters | 0 | 0 | 0 |
Number of participants with clinically significant abnormalities in vital signs were reported. Vital signs included body temperature, systolic / diastolic blood pressure, and pulse rate.
| Participants | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Vital Signs | 0 | 0 | 0 |
Number of participants with clinically significant abnormalities in 12-lead electrocardiogram (ECG) were reported. The 12-lead ECGs were recorded after the participants have rested for at least 5 minutes in supine position.
| Participants | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings | 0 | 0 | 0 |
Collected over Baseline up to Day 29. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cisticid | 0/60 (0%) | 0/60 (0%) | 2/60 (3.3%) |
| Biltricide First Administration | 0/60 (0%) | 0/60 (0%) | 5/60 (8.3%) |
| Biltricide Second Administration | 0/60 (0%) | 0/60 (0%) | 6/60 (10%) |
| Event | Cisticid | Biltricide First Administration | Biltricide Second Administration |
|---|---|---|---|
| NauseaGastrointestinal disorders | 0/60 | 0/60 | 2/60 |
| AnaemiaBlood and lymphatic system disorders | 0/60 | 2/60 | 0/60 |
| Joint injuryInjury, poisoning and procedural complications | 1/60 | 0/60 | 0/60 |
| HeadacheNervous system disorders | 1/60 | 0/60 | 1/60 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/60 | 0/60 | 1/60 |
| Aspartate Aminotransferase IncreasedInvestigations | 0/60 | 0/60 | 1/60 |
| Alanine Transaminase IncreasedInvestigations | 0/60 | 0/60 | 1/60 |
| Multiple injuriesInjury, poisoning and procedural complications | 0/60 | 0/60 | 1/60 |
| Head injuryInjury, poisoning and procedural complications | 0/60 | 1/60 | 0/60 |
| Abdominal painGastrointestinal disorders | 0/60 | 1/60 | 0/60 |
All participants who were randomized into the study.
| Age, Continuous(Years) | First Cisticid, Then Biltricide, Then Biltricide | First Biltricide, Then Cisticid, Then Biltricide | First Biltricide, Then Biltricide, Then Cisticid | Total |
|---|---|---|---|---|
| Mean | 27.80 ± 7.83 | 28.65 ± 7.46 | 27.20 ± 5.31 | 27.88 ± 6.86 |
| Sex: Female, Male(Participants) | First Cisticid, Then Biltricide, Then Biltricide | First Biltricide, Then Cisticid, Then Biltricide | First Biltricide, Then Biltricide, Then Cisticid | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 20 | 20 | 20 | 60 |
| Ethnicity (NIH/OMB)(Participants) | First Cisticid, Then Biltricide, Then Biltricide | First Biltricide, Then Cisticid, Then Biltricide | First Biltricide, Then Biltricide, Then Cisticid | Total |
|---|---|---|---|---|
| Hispanic or Latino | 20 | 20 | 20 | 60 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | First Cisticid, Then Biltricide, Then Biltricide | First Biltricide, Then Cisticid, Then Biltricide | First Biltricide, Then Biltricide, Then Cisticid | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 20 | 20 | 20 | 60 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2018 to primary completion in Jul 2018, 0 months.
Results were first posted in Sep 2019, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Praziquantel
Merck KGaA, Darmstadt, Germany →